Why the study?
What are the mechanisms of drug-induced cardiac arrhythmias associated with prokinetic agents, and how can these risks be mitigated?
What are the mechanisms of drug-induced cardiac arrhythmias associated with prokinetic agents, and how can these risks be mitigated?
This review highlights the cardiovascular safety concerns, specifically drug-induced arrhythmias, associated with several prokinetic agents and discusses mitigation strategies.
Answers are grounded in this paper and cite their sources.
Warrants QT monitoring with prokinetics; leaves open prospective validation of mitigation strategies.
BACKGROUND: Gastrointestinal sensorimotor dysfunction underlies a wide range of esophageal, gastric, and intestinal motility and functional disorders that collectively constitute nearly half of all referrals to gastroenterologists. As a result, substantial effort has been dedicated toward the development of prokinetic agents intended to augment or restore normal gastrointestinal motility. However, the use of several clinically efficacious gastroprokinetic agents, such as cisapride, domperidone, erythromycin, and tegaserod, is associated with unfavorable cardiovascular safety profiles, leading to restrictions in their use. PURPOSE: The purpose of this review is to detail the cellular and molecular mechanisms that lead commonly to drug-induced cardiac arrhythmias, specifically drug-induced long QT syndrome, torsades de pointes, and ventricular fibrillation, to examine the cardiovascular safety profiles of several classes of prokinetic agents currently in clinical use, and to explore potential strategies by which the risk of drug-induced cardiac arrhythmia associated with prokinetic agents and other QT interval prolonging medications can be mitigated successfully.
No takes yet. Share an insight, caveat, or question.
Giudicessi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: